Is BPC-157 Legal in 2026? Current FDA Status Explained

BPC-157 Current Legal Status

BPC-157 (Body Protection Compound-157) is legal to purchase in the United States when sold for in vitro laboratory research use. It is not a scheduled substance under the Controlled Substances Act, not an FDA-approved drug, and not banned by federal law.

Its regulatory history is more complex than most compounds in this category because it has been the subject of specific FDA actions — which has generated confusion about its status. Here's the precise current picture:

• Research compound purchases: Legal — no change expected from PCAC vote
• Controlled substance status: Not scheduled — not a DEA concern
• FDA-approved drug: No — investigational compound only
• Category 2 (compounding prohibition): Removed April 23, 2026
• 503A bulks list (compounding authorization): Not yet added — PCAC vote July 23, 2026
• Licensed pharmacy compounding: Not currently authorized — PCAC review pending

The Full Regulatory Timeline

2023: Category 2 Placement

In September 2023, FDA placed BPC-157 into Category 2 of its interim 503A policy. This was widely misreported as a "ban." What it actually meant: licensed compounding pharmacies could no longer legally prepare BPC-157 against prescriptions. Research compound vendors were unaffected. Gray market access continued.

February 2026: HHS Announces Review

HHS Secretary Robert F. Kennedy Jr. announced formal review of 14 Category 2 peptides. RFK Jr. has publicly named BPC-157 as a compound of personal interest, citing specific personal experience (L5 spine compression). This added political momentum to the review process.

April 23, 2026: Category 2 Removal

FDA removed BPC-157 (and 11 other compounds) from Category 2, effective April 23, 2026. This does not authorize compounding — it removes the specific prohibition and enables the PCAC review process. The compounding gray market remains legally ambiguous following this change.

June 30, 2026: FDA Staff Recommends Against

FDA career scientists released briefing documents recommending against BPC-157 for 503A listing, citing: no completed human RCTs, immunogenicity concerns for certain administration routes, and API characterization complexity. These are the FDA's scientific staff speaking — not the political layer.

July 23, 2026: PCAC Vote — PENDING

The PCAC meets at FDA White Oak Campus. Day 1 (July 23) covers BPC-157. The committee will hear nominator presentations, public testimony, deliberate, and vote a recommendation. This vote is advisory — FDA issues a binding rule typically 6–18 months later.

For live results: PCAC July 2026 Vote Results →

What the PCAC Vote Means for BPC-157

If the committee votes YES

FDA begins formal rulemaking to add BPC-157 to the 503A bulks list. Estimated timeline to licensed pharmacy availability: 6–18 months (late 2026 to mid-2027). This would create a legal compounding pharmacy pathway with physician prescription requirement. Research compound availability is unchanged.

If the committee votes NO

Compounding pharmacy pathway remains closed. BPC-157 cannot be legally prepared by 503A pharmacies. Research compound availability is unchanged. Nominators may re-submit with additional data in a future PCAC cycle.

If the committee DEFERS

Committee requests additional evidence or data before voting. Typically means a 6–12 month delay to the next review opportunity. Research compound availability unchanged.

In all three scenarios, Evo Peptides continues to offer BPC-157 for research purchase. The PCAC vote determines the pharmacy compounding channel, not the research compound channel.

FAQ